Fortrea Holdings, Inc. USDC – Southern District of New York june 11, 2025 CLASS PERIOD: july 3, 2023 – february 28, 2025LEAD PLAINTIFF DEADLINE: august 1, 2025 Please complete the form below to contact Kaplan Fox regarding the Fortrea Holdings Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox Alerts Investors to a Securities Class Action Against Fortrea Holdings Inc. (FTRE) – Deadline is August 1, 2025 Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) on behalf of investors that purchased or otherwise acquired Fortrea securities between July 3, 2023 and February 28, 2025 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Fortrea and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than August 1, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. On July 3, 2023, the start of the Class Period, Fortrea announced the completion of its spin-off from Labcorp Holdings Inc. (“Labcorp”) (the “Spin-Off”) and Fortrea stock began trading as a separate public company. At the time of the Spin-Off certain long-term projects in Fortrea’s portfolio remained ongoing (the “Pre-Spin Projects”). On March 3, 2025, Fortrea announced financial results for its fourth quarter and full year 2024. The Company disclosed that “targeted revenue and adjusted EBITDA trajectories for 2025 [were] not in line with [its] prior expectations.” During an earnings call that same day, the Company revealed that Pre-Spin projects are “late in their life cycle [and] have less revenue and less profitability than expected for 2025” and that “post-spin work is not coming on fast enough to offset the pre-spin contract economics.” The Company also said this will “continue to negatively impact [Fortrea’s] financial performance during 2025.” Following this news, the price of Fortrea stock fell $3.47 per share, or 25%, to close at $10.38 per share on March 3, 2025. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company’s 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the transition service agreements, or TSAs, with Labcorp; (iii) as a result, the Company’s previously announced EBITDA targets for 2025 were inflated; and (iv) the viability of the Company’s post-Spin-Off business model, as well as its business and/or financial prospects, were overstated. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Pamela A. Mayer*KAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. King*KAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Fortrea Holdings, Inc. See the Case Unicycive Therapeutics, Inc. See the Case Abacus Global Management, Inc. See the Case Red Cat Holdings, Inc. See the Case Ibotta, Inc. See the Case Krispy Kreme, Inc. See the Case UroGen Pharma Ltd. See the Case Iovance Biotherapeutics, Inc. See the Case 1-800-Flowers.com See the Case Compass Diversified Holdings See the Case SelectQuote and GoHealth, Inc. See the Case Take-Two Interactive Software, Inc. See the Case
